GB201805393D0 - Vaccine compositions - Google Patents

Vaccine compositions

Info

Publication number
GB201805393D0
GB201805393D0 GBGB1805393.4A GB201805393A GB201805393D0 GB 201805393 D0 GB201805393 D0 GB 201805393D0 GB 201805393 A GB201805393 A GB 201805393A GB 201805393 D0 GB201805393 D0 GB 201805393D0
Authority
GB
United Kingdom
Prior art keywords
vaccine compositions
vaccine
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1805393.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Priority to GBGB1805393.4A priority Critical patent/GB201805393D0/en
Publication of GB201805393D0 publication Critical patent/GB201805393D0/en
Priority to CA3069259A priority patent/CA3069259A1/en
Priority to CN201880063499.7A priority patent/CN111148532A/en
Priority to AU2018308607A priority patent/AU2018308607A1/en
Priority to PCT/EP2018/069669 priority patent/WO2019020493A1/en
Priority to EP18750351.1A priority patent/EP3658182A1/en
Priority to US16/751,635 priority patent/US20200155667A1/en
Priority to US18/142,697 priority patent/US20230270839A1/en
Ceased legal-status Critical Current

Links

GBGB1805393.4A 2017-07-27 2018-03-31 Vaccine compositions Ceased GB201805393D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB1805393.4A GB201805393D0 (en) 2018-03-31 2018-03-31 Vaccine compositions
CA3069259A CA3069259A1 (en) 2017-07-27 2018-07-19 Vaccine compositions
CN201880063499.7A CN111148532A (en) 2017-07-27 2018-07-19 Vaccine composition
AU2018308607A AU2018308607A1 (en) 2017-07-27 2018-07-19 Vaccine compositions
PCT/EP2018/069669 WO2019020493A1 (en) 2017-07-27 2018-07-19 Vaccine compositions
EP18750351.1A EP3658182A1 (en) 2017-07-27 2018-07-19 Vaccine compositions
US16/751,635 US20200155667A1 (en) 2017-07-27 2020-01-24 Vaccine compositions
US18/142,697 US20230270839A1 (en) 2017-07-27 2023-05-03 Vaccine compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1805393.4A GB201805393D0 (en) 2018-03-31 2018-03-31 Vaccine compositions

Publications (1)

Publication Number Publication Date
GB201805393D0 true GB201805393D0 (en) 2018-05-16

Family

ID=62142217

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1805393.4A Ceased GB201805393D0 (en) 2017-07-27 2018-03-31 Vaccine compositions

Country Status (1)

Country Link
GB (1) GB201805393D0 (en)

Similar Documents

Publication Publication Date Title
SG11202010821TA (en) Vaccine composition
GB201811312D0 (en) Compositions
ZA201801035B (en) Vaccine compositions
GB2586745B (en) Compositions
SG11202104306XA (en) Compositions
IL274975A (en) Immunostimulatory compositions
IL271603A (en) Immunogenic compositions
SG11202009259VA (en) Compositions
GB201809976D0 (en) Novel formulations
SG11202009147UA (en) Vaccine compositions
GB201802339D0 (en) Immunogenic composition
GB2562241B (en) Vaccine compositions
GB201803923D0 (en) Compositions
SG11202103389WA (en) Immunogenic compositions
GB201910794D0 (en) Vaccine
GB201811382D0 (en) Vaccine
GB201805676D0 (en) Compositions
GB201703529D0 (en) Vaccine composition
GB201911636D0 (en) Vaccine
GB201718251D0 (en) Vaccine Compositions
GB201819206D0 (en) Novel compositions
GB2570649B (en) Compositions
GB201803692D0 (en) Immunogenic composition
GB201809541D0 (en) Vaccine compositions
GB201805393D0 (en) Vaccine compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)